Breast Care最新文献

{"title":"Retraction Statement: Paper by Sabin Goktas Aydin, Ahmet Bilici, Omer Fatih Olmez, Basak B. Oven, Ozgur Acikgoz, Tansel Cakir, Pelin Basim, Asli Cakir, Yasin Kutlu, and Jamshid Hamdard entitled \"The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer\" [Breast Care. 2022;17(5):470-479. https://doi.org/10.1159/000524446].","authors":"","doi":"10.1159/000550972","DOIUrl":"10.1159/000550972","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1159/000524446.].</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"166"},"PeriodicalIF":2.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000547496","DOIUrl":"10.1159/000547496","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000546080.].</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"167-168"},"PeriodicalIF":2.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT.","authors":"Michael Braun, Oleg Gluz, Sherko Kuemmel, Ulrike Nitz, Kerstin Luedtke-Heckenkamp, Maren Darsow, Helmut Forstbauer, Silke Polata, Eva-Maria Grischke, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Christine Zu Eulenburg, Ronald Kates, Sandy Burmeister, Monika Graeser, Rachel Wuerstlein, Rick Baehner, Matthias Christgen, Hans Heinrich Kreipe, Nadia Harbeck","doi":"10.1159/000550825","DOIUrl":"10.1159/000550825","url":null,"abstract":"<p><strong>Introduction: </strong>In HR+/HER2- high-risk early breast cancer (eBC), the NATALEE and monarchE trials demonstrated improved survival after the addition of CDK4/6 inhibitors to endocrine treatment (ET). However, the absolute benefit varies according to prognostic factors. We analyzed the outcome of subgroups based on monarchE and NATALEE inclusion criteria in the WSG-ADAPT-HR+/HER2- trial investigating Ki67 response to ET in treatment decision.</p><p><strong>Methods: </strong>In WSG-ADAPT-HR+/HER2- (NCT01779206), HR+/HER2- eBC patients with cT2-4 or cN+ or G3 or baseline Ki67 ≥15% received 3-week induction ET. pN0-1 patients with RS 0-11 or RS 12-25 with ET-response (central Ki67_postET ≤10%) received ET alone (ET subtrial); patients with RS 12-25 and no ET-response received chemotherapy (CTx) in CTx subtrial. Patients with c/pN2-3 or G3 with Ki67 >40% were randomized directly to CTx subtrial evaluating (neo)adjuvant paclitaxel vs. nab-paclitaxel, followed by epirubicin + cyclophosphamide and ET. For this retrospective analysis, the intermediate-risk group (meeting NATALEE but not monarchE criteria for \"high risk\") included patients with N0 and T3-4 or T2 with G3, or RS >25 or baseline Ki67 ≥20%, and those with N1, T1-2, G1-2, and RS ≤25. The high-risk group (meeting monarchE criteria for \"high risk\") included remaining patients with node-positive eBC, and the low-risk group included remaining N0 patients.</p><p><strong>Results: </strong>In the CTx (<i>n</i> = 2,230) and ET subtrials (<i>n</i> = 2,135), 609 and 481 patients were at intermediate risk, and 963 and 303 were at high risk, respectively. Risk classifications were prognostic in ET and CTx subtrials (median follow-up: 60 months). Low-risk patients in the ET subtrial (<i>n</i> = 1,351) had 5-year invasive disease-free survival (iDFS) and distant DFS (dDFS) of 94.7% and 96.4%, respectively, vs. 90.1% and 93.6% for intermediate-risk patients, and vs. 88.3% and 88.9% for high-risk patients. In the CTx-subtrial, 5-year iDFS and dDFS rates were 93.9% and 94.9% in the low-risk group (<i>n</i> = 658), versus 84.7% and 87.0% in the intermediate-risk group, and 77.7% and 79.6% in the high-risk group. Survival outcomes were similar between pN0 and pN1 intermediate-risk patients in the ET and CTx subtrials.</p><p><strong>Conclusion: </strong>Among 4365 WSG-ADAPT-HR+/HER2- patients, N0-1 cases receiving ET after ET-response and meeting NATALEE but not monarchE criteria had only slightly inferior outcomes vs. the low-risk group. Assuming a hazard ratio of 0.7 for a ribociclib effect in NATALEE, an absolute benefit of approximately 2% fewer dDFS events after 5 years could be expected in this group based on the WSG-ADAPT-HR+/HER2- experience. ET-response evaluation can refine prognosis to better inform shared decision-making in this intermediate-risk group.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12981907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients Diagnosed with Sclerosing Adenosis in Core Needle Biopsies: When Should Excision Be Performed?","authors":"Kayra Cangoz, Ebru Menekse, Muhammed Bahadir Avci, Birol Korukluoglu","doi":"10.1159/000550847","DOIUrl":"10.1159/000550847","url":null,"abstract":"<p><strong>Introduction: </strong>Although sclerosing adenosis (SA) carries a minimal risk of invasive breast cancer, atypical lesions, ductal carcinoma in situ, and invasive carcinoma may coexist with it. The literature does not offer a clear consensus on whether such cases warrant routine excision or can be managed through surveillance. This research aimed to evaluate the efficacy of core needle biopsy (CNB) in detecting coexisting atypical or malignant lesions (A/ML) in patients diagnosed with SA, by comparing CNB results with those of secondary excisional biopsy. Additionally, it seeks to identify the preoperative factors associated with lesion coexistence, to help determine which cases require excision.</p><p><strong>Patients and methods: </strong>A retrospective analysis was conducted on 165 patients diagnosed with SA by CNB and subsequently underwent an excisional biopsy between May 2019 and September 2023 at Ankara Bilkent City Hospital, Turkey. The sensitivity and specificity of CNB in detecting A/ML coexisting with SA were evaluated. Preoperative risk factors and radiological characteristics were analyzed in a subgroup of patients with SA who showed no evidence of A/ML on CNB but subsequently underwent secondary excisional biopsy. This subgroup was dichotomized as benign or A/ML based on final pathology. Univariate and multivariate analyses were then performed to identify preoperative factors associated with lesion coexistence.</p><p><strong>Results: </strong>The sensitivity and specificity of CNB in detecting A/ML coexisting with SA were 55% and 89%, respectively. In the main subgroup, age at SA diagnosis based on CNB (ROC curve cutoff: 37.5 years), lesion size (ROC curve cutoff: 1.45 cm), and preoperative magnetic resonance imaging requirement were identified as significant predictors of coexisting A/ML in multivariate analysis. The likelihood of coexisting A/ML increased to 20.8% when two predictors were present and to 50.0% when all three were combined.</p><p><strong>Conclusion: </strong>Given the limited sensitivity of CNB in detecting A/ML coexisting with SA, excisional biopsy may be warranted for selected patients - particularly those with two or more preoperative risk factors.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormone Receptor Status as a Predictive Factor for Pathological Complete Response to Neoadjuvant Dual HER2 Blockade in Patients with HER2-Positive Breast Cancer: A Multicenter Retrospective Study.","authors":"Guojun Liu, Xuqun Huang, Qun Liang, Shaoping Liu","doi":"10.1159/000550380","DOIUrl":"10.1159/000550380","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant therapy with dual human epidermal growth factor receptor 2 (HER2) blockade using trastuzumab and pertuzumab combined with chemotherapy is the standard of care for patients with locally advanced HER2-positive breast cancer. However, responses vary among patients, particularly based on hormone receptor (HR) status. This study aimed to evaluate the predictive value of HR status for achieving pathological complete response (pCR) in this patient population.</p><p><strong>Methods: </strong>We conducted a multicenter, retrospective cohort study of patients with stage II-III HER2-positive breast cancer who received neoadjuvant trastuzumab and pertuzumab plus chemotherapy between January 2018 and December 2022. The primary endpoint was the pCR rate (ypT0/is ypN0). Secondary endpoints included breast conservation surgery (BCS) rate, objective response rate, and safety. Multivariate logistic regression analyses were performed to identify independent predictors of pCR, adjusting for potential confounders including chemotherapy regimen type. Event-free survival (EFS) was analyzed using the Kaplan-Meier method.</p><p><strong>Results: </strong>A total of 293 patients were included in the final analysis, with 170 (58.0%) being HR-positive (HR+) and 123 (42.0%) being HR-negative (HR-). The overall pCR rate was 48.1%. Patients in the HR-group achieved a significantly higher pCR rate than those in the HR+ group (65.0% vs. 35.9%; <i>p</i> < 0.001). The distribution of chemotherapy regimens (anthracycline-free vs. anthracycline-containing) was balanced between groups. In the multivariate analysis, HR- status (odds ratio [OR] = 3.10, 95% confidence interval [CI]: 1.82-5.30; <i>p</i> < 0.001), Ki-67 index >20% (OR = 2.01, 95% CI: 1.15-3.48; <i>p</i> = 0.012), and negative nodal status (OR = 1.85, 95% CI: 1.07-3.20; <i>p</i> = 0.026) were independent predictors of pCR. Chemotherapy regimen type was not a significant predictor. At a median follow-up of 36 months, the HR- group showed a trend toward better EFS (<i>p</i> = 0.043).</p><p><strong>Conclusion: </strong>HR status is a strong and independent predictor of pCR in HER2-positive breast cancer patients receiving neoadjuvant dual blockade. Patients with HR- disease derive the most benefit from this regimen, highlighting the need for tailored therapeutic strategies to improve outcomes for the HR+ subgroup.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Experience of Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in a Real-World Setting: European Patients' Perspectives.","authors":"Maggie Banys-Paluchowski, Diana Lüftner, Agnieszka Korfel, Nadia Chouaki, Isaac Sanderson, Sophie G Barlow, Alex Rider, Astra M Liepa, Christian Jackisch","doi":"10.1159/000547748","DOIUrl":"https://doi.org/10.1159/000547748","url":null,"abstract":"<p><strong>Introduction: </strong>This study evaluated the experiences of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer (EBC) in France, Germany, Italy, Spain, and the UK, including satisfaction with how well they are coping with their EBC, their wellbeing, knowledge and awareness of their disease, symptoms of treatment, and factors associated with coping.</p><p><strong>Methods: </strong>Data were collected cross-sectionally using a real-world, multinational, point-in-time observational study (2019 Adelphi EBC Disease Specific Programme^™ [DSP]) during June-October 2019. Physicians who manage/treat EBC completed online patient record forms (PRFs) and their patients were asked to complete a paper-based voluntary patient self-completion (PSC) form. Regression analyses were used to identify factors associated with coping with EBC.</p><p><strong>Results: </strong>Of 1,859 patients with PRFs, 925 (49.8%) completed a PSC and were the focus of this analysis. The majority (69.9%) of patients reported being satisfied with their coping with EBC and reported overall mean Functional Assessment of Cancer Therapy-Breast scores (scale 0-28) of 21.6 for physical wellbeing and 14.4 for functional wellbeing. Most patients (87.3%) reported being informed about at least one disease characteristic. Half of patients reported being actively involved in their breast cancer treatment decisions, although some patients (23.1% overall) reported being involved in these decisions, but they did not want to be. Physicians were a source of information on breast cancer for 89.9% of patients. Patients reported a wide range of symptoms, and 68.6% of patients reported that EBC had affected their ability to work. Ability to work (including work at home) was also the only actionable factor clearly associated with positive coping in our regression analysis. Significant differences among countries were found for almost all aspects evaluated.</p><p><strong>Conclusion: </strong>Most patients were satisfied with how well they were coping, which is encouraging. Despite the overall symptom burden, high health-related quality of life (HRQoL) was generally maintained, providing reassurance that adjuvant treatment approaches can be administered without detrimental effects on HRQoL. Joint decision-making may help some patients, but others may prefer less involvement in treatment decisions. Helping patients continue employment may be beneficial from both a personal and an economic perspective.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"21 1","pages":"41-48"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12908957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000549718","DOIUrl":"10.1159/000549718","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000548681.].</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"82"},"PeriodicalIF":2.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose Comparison (1 mL versus 2 mL) of Superparamagnetic Tracer for Sentinel Node Biopsy in Early Breast Cancer: Real-World Analysis from 456 Patients.","authors":"Ina Shehaj, Amelie Löwe, Paul Löwe, Anne-Sophie Heimes, Antje Lebrecht, Kathrin Stewen, Marcus Schmidt, Annette Hasenburg, Slavomir Krajnak","doi":"10.1159/000550609","DOIUrl":"https://doi.org/10.1159/000550609","url":null,"abstract":"<p><strong>Background: </strong>Superparamagnetic iron oxide (SPIO) tracers offer a radiation-free technique for sentinel lymph node biopsy (SNB) in early breast cancer (eBC). However, the data on optimal administration in daily practice, such as the optimal tracer volume and injection method, are still lacking.</p><p><strong>Methods: </strong>In this real-world data analysis, patients with clinically node-negative eBC who underwent SNB with SPIO (Magtrace®) between January 2020 and December 2022 were included. Primary endpoint was the impact of tracer volume on the detection rate. Secondary endpoints evaluated number of removed sentinel lymph nodes, surgical time, and the impact of tracer timing and body mass index (BMI) on detection rate.</p><p><strong>Results: </strong>A total of 456 patients were included in the study. Overall, 223 patients received 1 mL and 232 patients 2 mL of SPIO. The median time of tracer application was 4 days. Detection rates were similar between both groups (95.5% for 1 mL vs. 96.1% for 2 mL; <i>p</i> = 0.707), with a median of 2.0 sentinel nodes removed in both groups (<i>p</i> = 0.205). The median time of surgery was 70 min in the 1 mL group and 72 min in the 2 mL group, <i>p</i> = 0.972. The detection rate was 97.3% and 95.3% when tracer was injected before and after the median time of application, respectively (<i>p</i> = 0.286). BMI of ≥25 kg/m² led to a detection rate of 94.9% in the 1 mL group and 94.2% in the 2 mL group (<i>p</i> = 0.520).</p><p><strong>Conclusions: </strong>In this large real-world analysis, 1 mL and 2 mL were similar in the clinical performance of SNB in eBC. High detection efficacy was found regardless of tracer timing and BMI. This real-world analysis reinforces SPIO's role as an effective and adaptable alternative to conventional tracers in SNB for eBC.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12995379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity and Reliability Study of the Turkish Version of the Breast Cancer Stigma Scale: A Methodological Study.","authors":"Nurten Şişman, Zeynep Erdogan","doi":"10.1159/000550063","DOIUrl":"10.1159/000550063","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this methodological and descriptive study was to conduct the validity and reliability study of the Breast Cancer Stigma Scale (BCSS) for the Turkish population of breast cancer patients.</p><p><strong>Methods: </strong>The sample of the study consisted of 150 female patients who were diagnosed with breast cancer, met the inclusion criteria, and applied to the oncology clinics and outpatient units of a university hospital. Data were collected through face-to-face interviews using a 13-item personal information form investigating patients' sociodemographic and disease-related characteristics, the BCSS, and the Patient Health Questionnaire-9 (PHQ-9). Language and content validity, criterion validity, construct validity, and reliability analyses of the scale were conducted sequentially. Descriptive statistical methods (number, percentage, mean, standard deviation), correlation analysis, Kruskal-Wallis test, Mann-Whitney U test, <i>t</i>-test, Cronbach's alpha analysis, confirmatory factor analysis, and exploratory factor analysis were used for data analysis.</p><p><strong>Results: </strong>The content validity index (CVI) value was found to be 1.0. The factor loadings of the scale ranged between 0.663 and 0.892, and the total explained variance was 73.89%. The Turkish version of the BCSS demonstrated excellent internal consistency (Cronbach's α = 0.70-0.92) and good construct validity (CFA fit indices: CFI = 0.97, TLI = 0.96, RMSEA = 0.05, SRMR = 0.05). The Cronbach's alpha coefficients for the subscales of the BCSS were 0.92 for the Body-Image Impairment (BI) subscale, 0.70 for the Social Isolation (SI) subscale, 0.78 for the Discrimination (D) subscale, 0.89 for the Internalized Stigma (IS) subscale, and 0.90 for the total the BCSS score. The Turkish version of the scale showed a good fit with the original model, confirming its four-factor structure.</p><p><strong>Conclusion: </strong>The Turkish version of the BCSS was found to be valid and reliable.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12978814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147442816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Discussion: ABC8, Bridging the Gap.","authors":"Rachel Wuerstlein, Eva Schumacher-Wulf, Volkmar Müller, Orit Kaidar-Person, Renate Haidinger, Joana Mourato Ribeiro, Shani Paluch-Shimon","doi":"10.1159/000550030","DOIUrl":"10.1159/000550030","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12851627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146084305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}